Kiniksa Pharmaceuticals Ltd (KNSA) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Kiniksa Pharmaceuticals Ltd $13.58, price $76.08, upside -82.2%, quality 56 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Kiniksa Pharmaceuticals Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $7.60 – $80.92 · fair‑value band $7.95 – $20.22 · the $76.08 price screens above the $13.58 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Kiniksa Pharmaceuticals in your weekly email
Every Wednesday you see whether Kiniksa Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
Show more
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Stock analysis
Kiniksa Pharmaceuticals Ltd (KNSA) currently trades at $76.08, while our model-based Fair Value estimate is $13.58, implying the stock looks roughly 460.5% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $34.71 per share, and 0 of the 24 models we run sit above the $76.08 price.
Bear case: the Asset-Based group reads lowest at $4.82, and 24 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: $7.95 (bear) to $20.22 (bull), the price of $76.08 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 56/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Kiniksa Pharmaceuticals Ltd reported revenue of $678M in FY2025 versus $38.5M in FY2021, a compound +104.8%/yr. Reported net income was $59.0M in FY2025.
Key figures
Market cap $6.0B · P/E ratio 70.3 · P/S ratio 6.12 · EPS (TTM) $0.9100 · Net margin 8.7% · Return on equity 13.7% · Return on assets (EBIT) −13.5% · Operating margin 13.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 6% below its 52-week high and 114% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −82%, KNSA screens richer than that median.
Fair Value models
Bear $7.95Fair Value $13.58Bull $20.22
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.6657 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.68/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+60.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+45.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+144.8%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
+91.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+91.7%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−2,043% → 11%
Growth Forecast
A lot of optimism in the price
The price assumes less growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+53.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+21.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +49.8% a year for the price and +18.3% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (93 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
Compare Kiniksa Pharmaceuticals Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 626 stocks
Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score56 · Above median
Fair Value upside−82% · Bottom 25%
Profitability
Return on equity (TTM)14% · Top 25%
Return on assets8% · Top 25%
Net margin (TTM)10% · Above median
Operating margin (TTM)14% · Above median
Growth and dividend
Revenue growth56% · Top 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (TTM)70.3× · Priciest 25%
P/B10.59× · Priciest 25%
P/S (TTM)7.97× · Priciest 25%
P/FCF236.5× · Priciest 25%
EV/EBITDA61.6× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 14
FUTURE (revenue growth)100· sector 21
PAST (return on equity)55· sector 27
HEALTH (low debt)0· sector 96
DIVIDEND (yield)0· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Kiniksa Pharmaceuticals Ltd (KNSA) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $13.58 versus a price of $76.08, about −82% upside (overvalued).
What is the fair value of KNSA?
Our model-based fair value for Kiniksa Pharmaceuticals Ltd is $13.58 (as of Sep 24, 2026), built from audited fundamentals. The current price: $76.08.
What is the quality score of KNSA?
Kiniksa Pharmaceuticals Ltd has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Kiniksa Pharmaceuticals Ltd (KNSA)?
Our model-based price target is the fair value of $13.58 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario $7.95, optimistic scenario $20.22. It is a calculation from audited fundamentals, not an analyst target.
What is the Kiniksa Pharmaceuticals Ltd stock forecast for 2026?
Our models put fair value at $13.58, about −82% upside versus a price of $76.08 (overvalued). Cautious scenario $7.95, optimistic scenario $20.22. The calculation is refreshed regularly with new filings.
What is the revenue of Kiniksa Pharmaceuticals Ltd (KNSA)?
Kiniksa Pharmaceuticals Ltd reported trailing-twelve-month revenue of about $754M (latest available figure, as of Sep 24, 2026).
What growth is priced into Kiniksa Pharmaceuticals Ltd (KNSA)?
For today's price to be fair in a discounted-cash-flow model, Kiniksa Pharmaceuticals Ltd would have to grow free cash flow by +53.4 % per year for five years (discount rate 8.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +144.8 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of KNSA use?
Our models discount Kiniksa Pharmaceuticals Ltd at 8.5 %: a base by market capitalisation (mid), damped by beta 0.07, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Kiniksa Pharmaceuticals Ltd that is +53.4 % per year a year over ten years, using the same discount rate (8.5 %) and the same formula as our fair value.
How much growth has Kiniksa Pharmaceuticals Ltd (KNSA) delivered so far?
Over the past 5 years revenue at Kiniksa Pharmaceuticals Ltd grew +144.8 % a year. The price currently implies +53.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Kiniksa Pharmaceuticals Ltd (KNSA) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Kiniksa Pharmaceuticals Ltd (+53.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Kiniksa Pharmaceuticals Ltd (KNSA)?
The free-cash-flow yield on the price is 0.42 %: that much free cash flow Kiniksa Pharmaceuticals Ltd produces per unit of market value. When it exceeds the discount rate of our models (8.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Kiniksa Pharmaceuticals Ltd (KNSA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Kiniksa Pharmaceuticals Ltd it is $13.58 per share (as of Sep 24, 2026), against a price of $76.08. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Kiniksa Pharmaceuticals Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, KNSA trades above its calculated fair value: price $76.08, fair value $13.58, a gap of about −82% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of KNSA?
No. The price is what the market pays today ($76.08); the fair value is what the company's own numbers justify ($13.58). For Kiniksa Pharmaceuticals Ltd the two are $62.51 per share apart. That gap is exactly why we show both numbers side by side.
How much is Kiniksa Pharmaceuticals Ltd worth?
The market values Kiniksa Pharmaceuticals Ltd at about $6.0B (market capitalisation, as of Sep 24, 2026). Per share that is $76.08; our models calculate a fair value of $13.58 per share.
What do the bullish and bearish scenarios say about KNSA?
Our models span a range for Kiniksa Pharmaceuticals Ltd: cautious scenario $7.95, base $13.58, optimistic $20.22 per share (as of Sep 24, 2026, price $76.08). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of KNSA?
Kiniksa Pharmaceuticals Ltd trades at a price-to-earnings ratio of 70.3 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $13.58 is built from several models across several years. Other multiples: P/B 10.6, P/S 8.0, EV/EBITDA 61.6.
How solid is the balance sheet of Kiniksa Pharmaceuticals Ltd (KNSA)?
Balance-sheet figures for Kiniksa Pharmaceuticals Ltd (as of Sep 24, 2026): return on equity 13.7%. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is KNSA from its 52-week high?
Kiniksa Pharmaceuticals Ltd trades at $76.08, about 6% below its 52-week high of $80.92 and 114% above the low of $35.51 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $13.58 is for.
Which stocks are comparable to Kiniksa Pharmaceuticals Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Kiniksa Pharmaceuticals Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price $76.08, calculated fair value $13.58 (−82%), Quality Score 56/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of KNSA calculated?
We run Kiniksa Pharmaceuticals Ltd through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $13.58, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Kiniksa Pharmaceuticals Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Kiniksa Pharmaceuticals Ltd (KNSA)?
The closing price on Sep 23, 2026 was $76.08. Our model-based fair value is $13.58, about −82% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Kiniksa Pharmaceuticals Ltd right now?
The price sits above even our optimistic bull case ($20.22). The favourable scenario is already priced in. Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($7.95 to $20.22) leaves room in how you read the outcome.
Key figures of Kiniksa Pharmaceuticals Ltd
How large is the market capitalisation of Kiniksa Pharmaceuticals Ltd (KNSA)?
The market capitalisation of Kiniksa Pharmaceuticals Ltd is $6.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Kiniksa Pharmaceuticals Ltd (KNSA)?
The price-to-sales ratio of Kiniksa Pharmaceuticals Ltd is 6.12 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Kiniksa Pharmaceuticals Ltd (KNSA)?
Earnings per share at Kiniksa Pharmaceuticals Ltd are $0.9100 (price ÷ EPS = P/E 70.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Kiniksa Pharmaceuticals Ltd (KNSA)?
The net margin of Kiniksa Pharmaceuticals Ltd is 8.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Kiniksa Pharmaceuticals Ltd (KNSA)?
The return on equity (ROE) of Kiniksa Pharmaceuticals Ltd is 13.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Kiniksa Pharmaceuticals Ltd (KNSA)?
On an EBIT basis the return on assets of Kiniksa Pharmaceuticals Ltd is −13.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Kiniksa Pharmaceuticals Ltd (KNSA)?
The operating margin of Kiniksa Pharmaceuticals Ltd is 13.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Kiniksa Pharmaceuticals Ltd (KNSA)?
Revenue at Kiniksa Pharmaceuticals Ltd is growing +55.5% versus a year earlier (3y avg +45.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Kiniksa Pharmaceuticals Ltd (KNSA)?
Earnings per share at Kiniksa Pharmaceuticals Ltd are growing +146% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Kiniksa Pharmaceuticals Ltd (KNSA) hold?
Kiniksa Pharmaceuticals Ltd holds more cash than debt, $156M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Kiniksa Pharmaceuticals Ltd in the live analysis
One click puts Kiniksa Pharmaceuticals Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Some data
Sep 24, 2026